ClinicalTrials.gg
TerminatedNCT01986218Updated Sep 15, 2016

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of BMS-986115 in Various Advanced Cancer, sponsored by Bristol-Myers Squibb. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Why this study was terminated
(Non-safety reason, business objectives have changed)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the safety and effectiveness of daily doses of BMS-986115 in subjects with advanced solid tumors

02

Conditions studied

  • Various Advanced Cancer
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

  • Subjects with a or cytologically confirmed diagnosis of solid tumors, advanced or , to or relapsed from standard therapies or for which there is no known effective treatment
  • of at least 3 months
  • (ECOG) performance status score 0-1
  • Prior anti-cancer treatments are permitted (i.e., chemotherapy, radiotherapy, hormonal, or immunotherapy)
  • At least 4 weeks must have elapsed from last dose of prior anti-cancer therapy and the initiation of study therapy

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or suspected , primary brain tumors, or brain as the only site of disease
  • Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study medication
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease such as chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease. Non-chronic conditions (e.g. infectious diarrhea) that are completely resolved for at least 2 weeks prior to starting study treatment are not exclusionary
  • Any major surgery or gastrointestinal disease that would interfere with administration of oral medications
  • Conditions requiring chronic systemic use, such as disease or severe asthma, excluding inhalation steroids for maintenance.
  • Uncontrolled or significant cardiovascular disease
  • History of medically significant thromboembolic events or bleeding diathesis within the past 6 months
  • Inadequate bone marrow function ( (ANC) \< 1,500 cells/mm3; count \< 100,000 cells/mm3; \< 9.0 g/dL)
  • Inadequate hepatic function (Total > 1.5 times the institutional (ULN) (except known Gilbert's syndrome); (ALT) or aspartate transaminase (AST) > 2.5 times the institutional ULN. ALT or AST up to 3 times the institutional ULN permitted if total bilirubin is normal
  • Uncontrolled (≥ Grade 2) hypertriglyceridemia (fasting triglycerides > 300 mg/dL (3.42 mmol/L))
  • Inadequate renal function (Blood creatinine > 1.5 times the institutional ULN)
  • Positive blood screen for antibody, surface antigen, or (HIV) -1, -2 antibody
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm A: Dose Escalation (BMS-986115)

    Continuous daily dosing until disease progression or unacceptable toxicity

    Drug: BMS-986115

  • Experimental
    Arm A: Dose Expansion (BMS-986115)

    Continuous daily dosing until disease progression or unacceptable toxicity

    Drug: BMS-986115

  • Experimental
    Arm B: Dose Escalation (BMS-986115)

    Twice weekly dosing until disease progression or unacceptable toxicity

    Drug: BMS-986115

  • Experimental
    Arm B: Dose Expansion (BMS-986115)

    Twice weekly dosing until disease progression or unacceptable toxicity

    Drug: BMS-986115

Interventions

  • Also known as: BMS-986115 (Notch Inhibitor)

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of multiple daily doses of BMS-986115

    Measured by the frequency of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, Grade 3 or 4 AEs, deaths, laboratory abnormalities and clinically relevant electrocardiogram (ECG) changes from baseline

    Time frame: Up to 30 days after the last dose of study medication (approximately 18 months)

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  2. Time of maximum observed plasma concentration (Tmax) of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  3. Trough observed plasma concentration (Ctrough) of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  4. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  5. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  6. Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  7. Terminal plasma half-life (T-HALF) of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  8. Apparent total body clearance (CLT/F) of BMS-986115

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  9. Apparent volume of distribution at steady-state (Vz/F) of BMS-986115

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  10. AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986115

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  11. Ratio of metabolite AUC(INF) to parent AUC(INF) after single dose and ratio of metabolite AUC(TAU) to parent AUC(TAU) at steady state, corrected for molecular weight (MR_AUC) of BMS-986115 and its active metabolite BMT-100948

    Time frame: 29 timepoints up to Cycle 3 Day 1 (approximately 32 days)

  12. Pharmacodynamics (PD) changes in the expression of Notch pathway-related genes, including but not limited to Hes1 and Deltex1, as determined by standard molecular methods

    Time frame: 16 timepoints up to Cycle 2 Day 16 (approximately 20 days)

  13. Preliminary anti-tumor activity of BMS-986115 as measured by response evaluation criteria in solid tumors (RECIST)

    Assessed by: * Tumor Response based on the Investigator's assessment using RECIST v1.1 \[categorized as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD)\] * Best Overall Response (BOR), defined as the best tumor response recorded between the data of first dose and the last on-study tumor assessment (prior to any subsequent cancer therapy) * Overall Response Rate, defined as the proportion of subjects with BOR responses of CR or PR * Disease Control Rate, defined as the proportion of subjects with BOR responses of CR, PR or SD * Progression-Free Survival (or PFS), defined as time from first dose to either progressive disease, initiation of subsequent off-study therapy, or death

    Time frame: Screening (within 30 days prior to Day 1), Every 8 weeks, End of Treatment or 30-Day follow-up visits (approximately 18 months)

07

Study locations

4 sites
  • Usc/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Local Institution
    Parkville, Victoria 3050, Australia
  • Local Institution
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution
    Toronto, Ontario M5G 2M9, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2013
First posted
Nov 18, 2013
Start
Nov 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01986218
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Nov 2013
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Sep 15, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986115

Start the discussion